Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Invested Capital: 2021-2025

Historic Invested Capital for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to $161.8 million.

  • Prime Medicine's Invested Capital fell 14.61% to $161.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.8 million, marking a year-over-year decrease of 14.61%. This contributed to the annual value of $153.1 million for FY2024, which is 15.09% up from last year.
  • As of Q3 2025, Prime Medicine's Invested Capital stood at $161.8 million, which was up 165.89% from $60.9 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Invested Capital ranged from a high of $316.3 million in Q4 2022 and a low of -$223.1 million during Q3 2022.
  • Over the past 3 years, Prime Medicine's median Invested Capital value was $189.5 million (recorded in 2024), while the average stood at $178.0 million.
  • Examining YoY changes over the last 5 years, Prime Medicine's Invested Capital showed a top increase of 302.43% in 2022 and a maximum decrease of 136.29% in 2022.
  • Over the past 5 years, Prime Medicine's Invested Capital (Quarterly) stood at -$156.2 million in 2021, then skyrocketed by 302.43% to $316.3 million in 2022, then slumped by 57.92% to $133.1 million in 2023, then increased by 15.09% to $153.1 million in 2024, then dropped by 14.61% to $161.8 million in 2025.
  • Its Invested Capital stands at $161.8 million for Q3 2025, versus $60.9 million for Q2 2025 and $106.9 million for Q1 2025.